---
layout: default
title: Ropeginterferon Alfa-2B
parent: 僅模型預測 (L5)
nav_order: 873
evidence_level: L5
indication_count: 10
---

# Ropeginterferon Alfa-2B
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropeginterferon Alfa-2b: From Unrecorded Indication to Laubry-Pezzi Syndrome (Low-Confidence)

## One-Sentence Summary

> Ropeginterferon alfa-2b's original approved indication and mechanism of action are not recorded in this Evidence Pack (data gap), so the therapeutic rationale for any new indication cannot be independently verified here.
> The TxGNN model's top prediction is **Laubry-Pezzi syndrome** (a structural congenital heart defect), with a score of **99.93%**,
> but there are **0 clinical trials** and **0 publications** supporting this link, and the model's own rationale flags it as a likely false positive from sparse knowledge-graph connections.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded (drug not marketed in Singapore; `original_moa` and `original_indications` are data gaps) |
| Predicted New Indication | Laubry-Pezzi syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for ropeginterferon alfa-2b in this Evidence Pack. This is itself flagged as a **Blocking/High severity data gap** — without MOA and original indication data, we cannot independently assess mechanistic plausibility.

The Evidence Pack's own repurposing rationale for the top-ranked prediction is explicit and skeptical: Laubry-Pezzi syndrome is a structural congenital cardiac defect (ventricular septal defect with aortic regurgitation), whereas interferon alfa-2b's known pharmacology is antiviral, immunomodulatory, and antiproliferative. There is no plausible mechanism by which an interferon could reverse a fixed anatomical cardiac malformation. The rationale text concludes this high TxGNN score is likely an artifact of sparse knowledge-graph connectivity rather than a genuine biological signal.

This pattern repeats across nearly all top-10 predictions in this pack: congenital/structural anomalies (interventricular septum aneurysm, Pierre Robin syndrome, chromosomal deletions, orofacial clefting, pulmonary valve disease) that have no mechanistic link to interferon pharmacology and no supporting trials or literature. **None of the top-10 predictions in this pack meet a credible evidentiary bar.**

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

*(Note: rank 6 in this pack, "disorder of fucoglycosan synthesis," does carry 4 attached publications — but all 4 are actually about ropeginterferon alfa-2b in polycythemia vera, not the named disease. This is flagged in the pack itself as a likely disease-dictionary/ontology mapping error, not genuine evidence for the stated indication. See Conclusion below.)*

---

## Singapore Market Information

Ropeginterferon alfa-2b currently has **no registered license** in Singapore (`total_licenses: 0`, `licenses: []`). No product name, dosage form, or approved indication text is available from the local regulatory dataset.

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all marked as data gaps in this pack; DDI query returned no results.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- Evidence level is L5 across all top-10 predictions — model score only, with zero clinical trials and zero relevant literature.
- The top prediction (Laubry-Pezzi syndrome) and most others (structural/congenital/chromosomal disorders) have no plausible mechanistic link to interferon pharmacology, per the pack's own rationale.
- Blocking data gaps (TFDA label warnings/contraindications, original indication, MOA) prevent even a baseline safety (S1) review.
- The drug is not marketed in Singapore, so there is no local regulatory or use-pattern context to anchor this evaluation.

**To proceed, the following is needed:**
- Resolve DG001 (TFDA/label warnings and contraindications) and DG002 (MOA) before any further scoring.
- Correct the apparent disease-dictionary/ontology mapping error at rank 6 ("disorder of fucoglycosan synthesis" ↔ polycythemia vera literature) — this should be re-run through the mapping pipeline, as it may be masking a genuinely credible signal (polycythemia vera is a well-documented indication for this drug class) under an incorrect disease label.
- Re-screen predictions below the current top-10 for candidates with actual mechanistic plausibility and non-zero trial/literature support, since the top-10 by score are dominated by likely KG-sparsity artifacts.
- Obtain original indication and regulatory status from a source outside Singapore (e.g., EMA/FDA label) given zero local licenses.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

